ArticleOphthalmology. Retina2018
Fluorescence Lifetime Imaging Ophthalmoscopy: A Novel Way to Assess Macular Telangiectasia Type 2.
Article in Ophthalmology. Retina, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 66 citations in OpenAlex.
- Macular telangiectasia type 2: An update.The Journal of international medical research · 2026Review
- Evaluating the Influence of the Lens Autofluorescence on Adaptive Optics Fluorescence Lifetime Imaging Ophthalmoscopy.Translational vision science & technology · 2026Article
- Lifetime Standard for Fluorescence Lifetime Imaging Ophthalmoscopy.Translational vision science & technology · 2026Article
- Evaluating the Influence of the Lens Autofluorescence on Adaptive Optics Fluorescence Lifetime Imaging Ophthalmoscopy.medRxiv : the preprint server for health sciences · 2025Article
- Fluorescence Lifetime Imaging Ophthalmoscopy, Vision, and Chorioretinal Asymmetries in Aging and Age-Related Macular Degeneration: ALSTAR2.Investigative ophthalmology & visual science · 2025Article
- Fluorescence lifetime imaging ophthalmoscopy adds the retina to cortical pathology for visual dysfunction in neurodegenerative diseases.Frontiers in neurology · 2025Review
- Future applications of fluorescence lifetime imaging ophthalmoscopy in neuro-ophthalmology, neurology, and neurodegenerative conditions.Frontiers in neurology · 2025Review
- Brain-derived neurotrophic factor levels and macular ganglion cell-inner plexiform layer thickness in macular telangiectasia type 2.International ophthalmology · 2023Article
- Protein-Mediated Carotenoid Delivery Suppresses the Photoinducible Oxidation of Lipofuscin in Retinal Pigment Epithelial Cells.Antioxidants (Basel, Switzerland) · 2023Article
- Article
- Combining fluorescence lifetime with spectral information in fluorescence lifetime imaging ophthalmoscopy (FLIO).Biomedical optics express · 2022Article
- Suppression of natural lens fluorescence in fundus autofluorescence measurements: review of hardware solutions.Biomedical optics express · 2022Review
- Photobiology of lipofuscin granules in the retinal pigment epithelium cells of the eye: norm, pathology, age.Biophysical reviews · 2022Review
- Adaptive optics two-photon excited fluorescence lifetime imaging ophthalmoscopy of photoreceptors and retinal pigment epithelium in the living non-human primate eye.Biomedical optics express · 2022Article
- The Development and Clinical Application of Innovative Optical Ophthalmic Imaging Techniques.Frontiers in medicine · 2022Review
- The Role of Diagnostic Imaging in Macular Telangiectasia Type 2.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021Article
- Current status and future possibilities of retinal imaging in diabetic retinopathy care applicable to low- and medium-income countries.Indian journal of ophthalmology · 2021Review
- Method for controlled tissue theranostics using a single tunable laser source.Biomedical optics express · 2021Article
- Fluorescence Lifetime Changes Induced by Laser Irradiation: A Preclinical Study towards the Evaluation of Retinal Metabolic States.Life (Basel, Switzerland) · 2021Article
- Comparing Fluorescence Lifetime Imaging Ophthalmoscopy in Atrophic Areas of Retinal Diseases.Translational vision science & technology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeMacular Telangiectasia Type 2 (MacTel) is an uncommon, late-onset complex retinal disease that leads to central vision loss. No causative gene(s) have been identified so far, resulting in a challenging clinical diagnostic dilemma because retinal changes of early stages are often subtle. The objective of this study was to investigate the benefit of fluorescence lifetime imaging ophthalmoscopy (FLIO) for retinal imaging in patients with MacTel.
designCross-sectional study from a tertiary-care retinal referral practice. SUBJECTS AND CONTROLS: 42 eyes of 21 patients (mean age 60.5±13.3 years) with MacTel as well as an age-matched healthy control group (42 eyes of 25 subjects, mean age 60.8±13.4 years).
methodsA 30° retinal field centered at the fovea was investigated using FLIO. This camera is based on a Heidelberg Engineering Spectralis system. Fundus autofluorescence (FAF) decays were detected in short (498-560 nm, SSC) and long (560-720 nm, LSC) spectral channels. The mean fluorescence lifetime, τ
main outcome measuresMean FAF lifetime (τ
resultsFLIO of MacTel patients shows a unique pattern of prolonged τ
conclusionsFLIO detects retinal changes in patients with MacTel with high contrast, presenting a distinctive signature that is a characteristic finding of the disease. The non-invasive properties of this novel imaging modality provide a valuable addition to clinical assessment of early changes in the disease that could lead to more accurate diagnosis of MacTel.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.